| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/12/2022 | 226.09% | EF Hutton | → $6 | Initiates Coverage On | → Buy |
What is the target price for Coeptis Therapeutics (COEP)?
The latest price target for Coeptis Therapeutics (NASDAQ: COEP) was reported by EF Hutton on December 12, 2022. The analyst firm set a price target for $6.00 expecting COEP to rise to within 12 months (a possible 226.09% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Coeptis Therapeutics (COEP)?
The latest analyst rating for Coeptis Therapeutics (NASDAQ: COEP) was provided by EF Hutton, and Coeptis Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for Coeptis Therapeutics (COEP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Coeptis Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Coeptis Therapeutics was filed on December 12, 2022 so you should expect the next rating to be made available sometime around December 12, 2023.
Is the Analyst Rating Coeptis Therapeutics (COEP) correct?
While ratings are subjective and will change, the latest Coeptis Therapeutics (COEP) rating was a initiated with a price target of $0.00 to $6.00. The current price Coeptis Therapeutics (COEP) is trading at is $1.84, which is within the analyst's predicted range.